Boston Scientific (NYSE: BSX) is scheduled to report its Q3 2024 results on Wednesday, October 23. We expect the company to report revenues and earnings slightly below the consensus estimates.

If you’re on the fence about investing in Boston Scientific Corporation or Thermo Fisher Scientific Inc ... cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, ...

Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares fell Wednesday as its third-quarter profit missed estimates. The medical device maker's adjusted earnings per share and ...

Boston Scientific is launching the Farawave Nav ablation catheter and Faraview software to treat atrial fibrillation in the U.S. · MedTech Dive · Courtesy of Boston Scientific Boston Scientific ...

Boston Scientific (NYSE: BSX) + today reported third-quarter results that came in ahead of the consensus forecast, raising its 2024 guidance again. The company’s CEO also said on its third ...

Boston Scientific Stock Prediction For 2024 Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the ...

Good morning and welcome to the Boston Scientific Third Quarter 2024 Earnings ... FDA approval in the quarter and our EMPOWUR leadless pacemaker, which we now have submitted to the FDA.

If you’re on the fence about investing in Boston Scientific Corporation or Edwards Lifesciences Corporation because ... cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, ...

Boston Scientific (BSX) announced it has entered into a definitive agreement to acquire Cortex, Inc., an Ajax Health company. Cortex is a privately held medical technology company focused on the ...

The Farapulse Farawave catheter and Faraview software. [Image courtesy of Boston Scientific] Boston Scientific (NYSE: BSX) + announced today that it received FDA approval for its navigation ...